Tagged with Canada

Pricing Pushback from drug companies on Canada’s newest drug pricing regulations has led the country’s regulatory body to reconsider their implementation. Companies cite the push for cost-effectiveness as a reason for withdrawing drug approval applications, cutting jobs, or delaying launches, claiming the new pricing regulations will substantially reduce revenues.    The…

Canada Dr Neil Cashman looks at the potential impact of US FDA approval for Biogen’s aducanumab on the search for Alzheimer’s Disease (AD) treatments, and how Canada is playing a leading role in the development of the next generation of AD therapies.   We’re at the advent of a potential landmark…

Canada John L. Wallace of Antibe Therapeutics highlights how Canadian innovation stands to put the country at the forefront of the next wave of global biopharmaceutical R&D. BlueRock Therapeutics, a promising North American start-up with a new Parkinson’s disease drug, was recently sold to Germany’s Bayer at a $1 billion valuation.…

Canada Pamela Fralick of Innovative Medicines Canada (IMC) advocates for a collaborative multi-stakeholder approach to better tackle rare diseases in Canada.   Especially in smaller provinces, it’s virtually impossible to predictably manage the affordability and accessibility of drugs necessary to treat rare disease Around the world, rare diseases are becoming easier…

Canada Marina Vasiliou took the reins as managing director of Biogen Canada in November 2017 after a long and varied career at MSD in a wide variety of geographies.   Canada’s biggest strengths are its diversity and openness—whether that is in health sciences or the culture itself Marina Vasiliou, Biogen Vasiliou…

Canada Diabetes Canada’s Jan Hux outlines how her organization has been able to shift from small, local programs to driving change at a much larger level via a ‘collective impact’ approach.   When I encountered the concept of collective impact in the Stanford Social Innovation Review, I realized the possibilities lay…

Canada A new white paper from Fasken law firm asserts that the early filing of patents for innovative products is crucial for companies hoping to succeed in the booming North American cannabis market   Canada’s decision to legalise cannabis for recreational use in 2018 is set to spur on the already…

Canada It is not a secret anymore, many in the industry now know that Health Canada is working on a new version of the policy entitled: The Distinction Between Advertising and Other Activities, dated more than 20 years ago. Earlier this week, Health Canada provided some insights about the reformed policy…

Canada Canada is the only developed country with a universal healthcare system that does not provide universal coverage of prescription drugs. With a new national ‘pharmacare’ program being proposed to remedy this situation, Pamela Fralick of Innovative Medicines Canada outlines the strengths and weaknesses of the proposal on the table and…

Opinion In the light of several recent regulatory updates to Canada’s cannabis laws, lawyer Jean-Raphaël Champagne examines the potential for cannabis to be legalised for use in cosmetic products in Canada.   One thing that Bill C-51 did not change was the relationship between cannabis substances and cosmetic products in Canada…

Opinion Jan Hux, the president and CEO of Diabetes Canada calls for governments to place greater importance on partnerships with patient groups for the making of big decisions in healthcare.    The establishment of a multi-stakeholder group, including patient organizations and patient representatives, could provide feedback and public policy recommendations to…

Canada Durhane Wong-Rieger is the President & CEO of the Canadian Organization for Rare Disorders (CORD). In her first article for PharmaBoardroom, Durhane explains the changing landscape for access to rare disease drugs in Canada and the actors involved in getting there.   The irony of the government processes, which, on…